Astellas制药公司在日本提出前列腺癌疗法
- 互联网2012年11月5日 15:37 点击:1487
Astellas制药公司在日本推出了新药Gonax ,作为促性腺激素受体阻断皮下注射剂,用于治疗前列腺癌。
Astellas Pharma unveils prostate cancer therapy in Japan
PBR Staff Writer Published 22 October 2012
Astellas Pharma has introduced Gonax (Degarelix Acetate), a gonadotrophin-releasing hormone (GnRH)-receptor blocker, for subcutaneous injection to treat prostate cancer in Japan.
Gonax is designed to inhibit the binding of GnRH, a hormone produced by the hypothalamus in the brain, to the specific receptors thereby restraining the testosterone production and finally controlling the prostate cancer growth.
The data obtained from Phase-III trial conducted abroad besides Phase I and Phase II studies conducted in Japan has formed the basis for filing a market authorization application.
The studies demonstrated that Gonax maintained the blood testosterone levels below castration from third day till the whole treatment period eliminating the testosterone flow.
Gonax also demonstrated a satisfactory safety profile in the studies.
联系邮箱:kefu@labbase.net
版权与免责声明
- 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.labbase.net,违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。